Dana Launches New Cerebrum Podcast

E-May-Epilepsy

For almost a year, we’ve featured the authors of our monthly Cerebrum articles in a Q & A. With the May Cerebrum article, “A New Approach for Epilepsy,” we are transitioning to a podcast.

Why are we taking this new approach? We suspect that visitors to the website, with already quite a bit to read, will welcome an audio option. We also think it will be valuable to hear some of the top researchers in the field offer their opinions and explain some of the complex biological, neurochemical, or genetic advances that they write about in Cerebrum, the Dana Foundation’s research-based publication.

Continue reading

The Epilepsy Conundrum

Robert Gumnit, M.D., founder of the first comprehensive epilepsy center in the United States, says the way patients and doctors deal with seizures is like a comedy routine, except it’s not funny: a man has a seizure and thinks to himself, That’s odd. If it happens again I’ll tell my wife. It happens again, so he tells his wife; she says, That’s odd. If it happens again you should tell a doctor. It does, so he tells his doctor, who might say, I’m not sure what happened to you. Why don’t we wait to see if it happens again?

“As a result,” Gumnit says, “the identification of the patient who needs treatment is delayed, often by many, many years. That puts the patient behind the 8-ball because the more seizures you have, the harder they are to treat.”

Continue reading

Lights on, brain off

If you’re a night owl like me, then those first rays of
sunshine in the morning often seem to make you feel even groggier than you did
when you went to bed. But scientists have found a new, efficient way to use
simple beams of light to literally—not just metaphorically—shut down the brain.

Ed Boyden, a research
professor at the Massachusetts Institute of Technology, and his colleagues have
discovered two new light-sensitive proteins that, when implanted into neurons,
prevent those cells from activating in the presence of certain wavelengths of
light. Arch, found in a species of bacteria, is sensitive to yellow light,
whereas Mac is of fungal origin and responds to blue light, the scientists
report
in the Jan. 7 issue of Nature.

Arch
A mouse neuron expressing Arch

These proteins, Boyden says, will not only provide
scientists with a powerful but reversible way to study specific brain regions,
but may also provide promising new gene therapy treatments for diseases caused
by overactive brain cells. One of the most drastic examples of such a disorder
is epilepsy,
in which spontaneous activity by neurons can sometimes spread throughout the
entire brain, causing violent seizures and occasionally death.

These aren’t the first light-sensitive proteins, or opsins,
that neuroscientists have adapted to their purposes. For some time, researchers
have been using opsins to both selectively activate and inhibit brain cells, a
field known as optogenetics. As we reported last month,
such techniques allow scientists to study the function of specific brain cells,
such as those involved in memory or disease, with greater detail and precision
than previously possible.

Opsins work because they are ion channels; when activated,
they allow charged particles into a cell. In the case of ChR2, blue light
causes an influx of charged particles that mimic what naturally occurs when a
neuron is told to fire. Halorhodopsin, on the other hand, adds chloride ions to
a cell’s interior that make it unable to send a signal. Halorhodopsin, however,
quickly becomes inactive in the presence of light, whereas the new proteins,
which allow protons into cells, “reset” themselves and can shut off cells for
very long periods of time. “These are an order of magnitude better,” Boyden
says. “They allow for near-digital turning off of neurons in awake animal
cortexes.”

In the Nature
paper, Boyden and his colleagues demonstrate the use of Arch and Mac in awake
mice, but he says that the team has also conducted tests in nonhuman primates
with no apparent side effects yet.  They
are also “very eager” to begin studying prototype therapies in mouse models for
epilepsy, chronic pain, brain injuries, and other brain diseases, he adds.
Opsins are normally implanted using gene therapy, in which a retrovirus is used
to insert the opsin-producing gene into the relevant brain cells. In recent
years, scientists have significantly improved their gene therapy techniques—for
instance, they can now target the right cells by altering the protein coat of
the virus or by adding different DNA promoter regions to the implanted
gene—Boyden says, and thus the risk of side effects such as cancer has dropped
dramatically.

Another benefit of the new long-lasting proteins, he adds,
is that scientists can now precisely and reversibly shut off small regions of
the brain to study their roles in activities like cognition and attention—essentially,
a “high-throughput scan for the brain.” Previously, scientists have obtained this
information largely by looking at lesions, but these are relatively large and
haphazard and provide no information about timing. “It’s like pulling the power
cord of a laptop. You don’t know if it’s the lack of a power or the processing
input causing the problem,” Boyden says. “We believe this will have a
significant effect on neuroscience.”

—Aalok Mehta

Image courtesy of Brian Chow, Xue Han and Ed Boyden / MIT

%d bloggers like this: